ArticleNature communications2014
Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity.
Article in Nature communications, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 263 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
263 citing papers in PubMed.
- PEG-associated efficacy loss in lipid nanoparticles persists across formulation modifications for mRNA delivery.Drug delivery and translational research · 2026Article
- Structural evolution of ionizable lipids for nucleic acid delivery.Nature reviews. Chemistry · 2026Review
- Ligand-Mediated Reprogramming Redirects Liver-Tropic Ionizable Lipid Nanoparticles for Lung-Selective mRNA Delivery.Angewandte Chemie (International ed. in English) · 2026Article
- Elucidating lipid nanoparticle properties and structure through biophysical analyses.Nature biotechnology · 2026Article
- RNA Size and Structure Modulate the Apparent pKa of Ionizable Lipid Nanoparticles.Bioconjugate chemistry · 2026Article
- PEG-associated efficacy loss in lipid nanoparticles persists across formulation modifications for mRNA delivery.Research square · 2026Article
- Combating VEGFA-siRNA-Induced Metabolic Reprogramming via Glucose Utilization Deprivation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Decoding Undesirable Inflammatory Responses of Nucleic Acid-Delivering Lipid Nanoparticles.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- mRNA vaccines for viral diseases: mechanism, advances, and future perspective.Molecular biology reports · 2026Review
- Suppression of PARP1 enhances PTEN mRNA therapy in castration-resistant prostate cancer by glycolysis disruption.Molecular therapy. Oncology · 2026Article
- Transformer-based multidimensional feature fusion for accurate prediction of lipid nanoparticles transfection efficiency.Briefings in bioinformatics · 2026Article
- Investigating the impact of hypoxia and syncytialization on lipid nanoparticle-mediated mRNA delivery to placental cells.Bioengineering & translational medicine · 2026Article
- Lipid Nanoparticle Database towards structure-function modeling and data-driven design for nucleic acid delivery.Nature communications · 2026Article
- Dendrimers Improve Apolipoprotein Nanoparticle mRNA Delivery to Immune Cells.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- A Comprehensive Dataset of Lipid Nanoparticle Compositions and Properties for Nucleic Acid Delivery.Scientific data · 2025Article
- Degradable cyclic amino alcohol ionizable lipids as vectors for potent influenza mRNA vaccines.Nature nanotechnology · 2025Article
- Artificial intelligence-guided design of lipid nanoparticles for pulmonary gene therapy.Nature biotechnology · 2025Article
- Elucidating lipid nanoparticle properties and structure through biophysical analyses.bioRxiv : the preprint server for biology · 2025Article
- Designing lipid nanoparticles using a transformer-based neural network.Nature nanotechnology · 2025Article
- Targeting and tracking mRNA lipid nanoparticles at the particle, transcript and protein level.Nature biomedical engineering · 2025Review
203 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
One of the most significant challenges in the development of clinically viable delivery systems for RNA interference therapeutics is to understand how molecular structures influence delivery efficacy. Here, we have synthesized 1,400 degradable lipidoids and evaluate their transfection ability and structure-function activity. We show that lipidoid nanoparticles mediate potent gene knockdown in hepatocytes and immune cell populations on IV administration to mice (siRNA EC50 values as low as 0.01 mg kg(-1)). We identify four necessary and sufficient structural and pKa criteria that robustly predict the ability of nanoparticles to mediate greater than 95% protein silencing in vivo. Because these efficacy criteria can be dictated through chemical design, this discovery could eliminate our dependence on time-consuming and expensive cell culture assays and animal testing. Herein, we identify promising degradable lipidoids and describe new design criteria that reliably predict in vivo siRNA delivery efficacy without any prior biological testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.